Related content

Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease

By Boudes Audrey   Lavoute Cécile   Avierinos Jean-François   Le Dolley Yvan   Villacampa Chloe   Salem Adrien   Loundou Anderson Dieudonné   Michel Nicolas   Renard Sébastien   Habib Gilbert  

European Journal of Echocardiography, Vol. 12, Iss. 9, 2011-09 ,pp. : 688-695

Oxford University Press

Access to resources Recommend Favorite

Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas

By Vallette Sophie   Serri Karim   Rivera Juan   Santagata Patricia   Delorme Sophie   Garfield Natasha   Kahtani Nora   Beauregard Hugues   Aris-Jilwan Nahla   Houde Ghislaine   Serri Omar  

Pituitary, Vol. 12, Iss. 3, 2009-09 ,pp. : 153-157

Springer Publishing Company

Access to resources Recommend Favorite

Ventricular fibrillation induction by transesophageal stimulation in a patient with valvular heart disease

By Brembilla-Perrot B.   Henneton C.  

Annales de Cardiologie et d'Angeiologie, Vol. 52, Iss. 6, 2003-12 ,pp. : 379-381

Elsevier

Access to resources Recommend Favorite

What can we learn about valvular heart disease from PET/CT?

By Jenkins William SA   Chin Calvin   Rudd James HF   Newby David E   Dweck Marc R  

Future Cardiology, Vol. 9, Iss. 5, 2013-09 ,pp. : 657-667

Future Medicine

Access to resources Recommend Favorite

Malondialdehyde-Modified LDL IgG Antibody Levels and Indices of Cardiac Function in Valvular Heart and Coronary Artery Disease Patients

By  

Medical Principles and Practice, Vol. 24, Iss. 5, 2015-06 ,pp. : 424-431

Karger

Access to resources Recommend Favorite